Dreamit is a leading venture fund focused on startups with revenue or pilots that are ready to scale. Dreamit specializes in startups building transformative companies in Securetech. Founders meet with dozens of potential customers and partners on Customer Sprints® and pitch leading venture firms during Investor Sprints®. Since its founding in 2008, Dreamit has partnered and helped grow over 320 startups, including LevelUp (acquired by GrubHub), Trendkite (acquired by Cision), SeatGeek, HouseParty (acquired by Epic Games), Elevate, Adaptly (acquired by Accenture), Wellth, Biomeme, Tissue Analytics (acquired by Net Health), Redox, Eko Devices, NestEgg, Cherre, Cylera, RaySecur, SpecTrust, Tidal Cyber, TestifySec, Nirmata, and Accuknox.

Dreamit Ventures

Knudsen Capital is a family investment office that primarily invests in early-stage, high-growth companies. The firm is driven by three key criteria for investing which include purpose, people, and profit. Knudsen Capital was co-founded by Brent Knudsen and Webb Knudsen in 2016.

Knudsen Capital

Bling Capital is a venture capital investment firm based in the San Francisco Bay Area, California. It primarily invests in consumer tech, internet, mobile, marketplace, data, fintech, SaaS, and automation sectors.

Bling Capital

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

7G Bioventures is a venture capital firm that focuses on healthcare innovation, prevention, and digital healthcare.

7G Bioventures

Curbside Health

Curbside Health develops clinical decision support software that aligns health systems and clinicians to more efficiently deliver optimal care.  The company was founded by physicians and technologists to combine the best of clinical evidence with the realities of healthcare delivery and with opportunities of modern web technology.  We support health systems and hospitals to expand their clinical content library (e.g. clinical pathways, protocols, guidelines, A3s, checklists, etc) and enhance the utilization of these resources at the point-of-care. Together, the components of Curbside's platform enable a hospital to improve clinical outcomes and operational efficiencies.  Product development is informed by working closely with patients, clinicians, engineers, physicians, healthcare administrators, and payors.  Our mission is hiding in plain sight within our name, and those in healthcare will understand: every medical decision is informed in real-time by the world's expert of that particular situation, while simultaneously accounting for hospital policy and all relevant patient-specific data.  Essentially, Curbside is on a never-ending quest to perfect medical decision making.

Curbside Health is a healthcare technology company that provides a clinical pathway solution for healthcare organizations. The company's platform allows medical professionals to access, customize, and deploy clinical pathways and guidelines across their organizations. Curbside's solution enables the discovery and sharing of clinical content from leading medical centers, with tools for customizing pathways to fit specific organizational needs. The platform integrates with electronic health record (EHR) systems, allowing clinicians to access pathways and place orders at the point of care. Curbside utilizes SMART on FHIR technology to integrate with EHR ecosystems like Epic and Cerner. The company's analytics capabilities allow organizations to track utilization and outcomes of clinical pathways. In November 2022, Curbside announced a partnership with Memorial Sloan Kettering Cancer Center to deploy its platform across multiple aspects of MSK's clinical practice.

What’s the Difference Between Curbside Consultations and eConsults?

A Safer Alternative: eConsults

‎Curbside Health

Memorial Sloan Kettering Cancer Center Partners with Curbside Health

‎The Curbsiders Internal Medicine Podcast on Apple Podcasts

Curbside: Matching Physicians with Expert Lenders & Realtors

“Curbside” veterinary care during COVID

Medical Gas Delivery & Curbside Pickup

TeleVisits Change Chesterfield Healthcare

NEW Health Curbside Care

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

OSF HealthCare Implements Curbside Health to Advance Clinical Guidelines & Support Patient Care Excellence

Curbside Health is a healthcare technology company that provides a clinical pathway solution for healthcare organizations. The company's platform allows medical professionals to access, customize, and deploy clinical pathways and guidelines across their organizations. Curbside's solution enables the discovery and sharing of clinical content from leading medical centers, with tools for customizing pathways to fit specific organizational needs. The platform integrates with electronic health record (EHR) systems, allowing clinicians to access pathways and place orders at the point of care. Curbside utilizes SMART on FHIR technology to integrate with EHR ecosystems like Epic and Cerner. The company's analytics capabilities allow organizations to track utilization and outcomes of clinical pathways. In November 2022, Curbside announced a partnership with Memorial Sloan Kettering Cancer Center to deploy its platform across multiple aspects of MSK's clinical practice.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

In most cases, CDSSs are provided to healthcare providers

Uses digital mediums to generate actionable insights from health data

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Uses IoT to connect databases with medical devices for decision support

Curbside Health

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless